for people ages 18 years and up (full criteria)
at Orange, California and other locations
study started
completion around



This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL).

This study will be made up of two parts: Part 1 (non-randomized) and Part 2 (randomized - controlled). The aim of Part 1 of the study is to see how safe and tolerable the study drug is. The aim of Part 2 of the study is to see how the study drug works compared to rituximab and chemotherapy (the current standard of care for NHL). Standard of care means the usual medication expected and used when receiving treatment for a condition.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in your blood at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
  • The impact from the study drug on your quality of life and ability to complete routine daily activities.

Official Title

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 X Anti-CD3 Bispecific Antibody Versus Investigator's Choice in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-1)


Follicular Lymphoma (FL), Non-Hodgkin lymphomas (NHLs), Indolent NHL, B-cells NHL (B-NHL), Follicular lymphoma, Odronextamab, Lymphoma, Prednisone, Prednisolone, Cyclophosphamide, Bendamustine Hydrochloride, Rituximab, Doxorubicin, Vincristine, Prednisone/prednisolone, Bendamustine


You can join if…

Open to people ages 18 years and up

  1. Diagnosis of cluster of differentiation 20^+ (CD20^+) FL Grade 1-3a, stage II bulky or stage III / IV
  2. Need for treatment as described in the protocol
  3. Have measurable disease on cross-sectional imaging documented by diagnostic imaging Computed tomography (CT) or Magnetic resonance imaging (MRI)
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  5. Adequate bone marrow function and hepatic function

You CAN'T join if...

  1. Central nervous system (CNS) lymphoma or leptomeningeal lymphoma
  2. Histological evidence of transformation to a high-grade or diffuse large B-cell lymphoma
  3. Waldenström macroglobulinemia (WM, lymphoplasmacytic lymphoma), Grade 3b follicular lymphoma, chronic lymphocytic leukemia, or small lymphocytic lymphoma
  4. Treatment with any systemic anti-lymphoma therapy
  5. Infections and allergy/hypersensitivity to study drug or excipient

    NOTE: Other protocol defined inclusion / exclusion criteria apply


  • University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center accepting new patients
    Orange California 92868 United States
  • The University of Texas Health Science Center at Tyler D/B/A UT Health East Texas HOPE Cancer Center accepting new patients
    Tyler Texas 75701 United States


accepting new patients
Start Date
Completion Date
Regeneron Pharmaceuticals
Phase 3 Lymphoma Research Study
Study Type
Expecting 478 study participants
Last Updated